Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

August

6

TriSalus Life Sciences Reports Second Quarter 2026 Results

Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and...

29

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

WESTMINSTER, Colo.–(BUSINESS WIRE)–Jul. 29, 2026– TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the...

16

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

WESTMINSTER, Colo.–(BUSINESS WIRE)–Jul. 16, 2026– TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company...

10

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

Newly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced...

12

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

Generated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and...

12

Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance

Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated...

4

TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

WESTMINSTER, Colo.–(BUSINESS WIRE)–May 4, 2026– TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company...

28

TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call

Conference Call and Webcast Scheduled for Tuesday, May 12, 2026 at 4:30 PM WESTMINSTER, Colo.–(BUSINESS WIRE)–Apr....

9

TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

WESTMINSTER, Colo.–(BUSINESS WIRE)–Apr. 9, 2026– TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company...

18

TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models

DENVER–(BUSINESS WIRE)–Mar. 18, 2026– TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating...

5

TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance

Reports $13.2 million in Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of...

20

TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering

WESTMINSTER, Colo.–(BUSINESS WIRE)–Feb. 20, 2026– TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an...